All times are listed in CEST (Central European Summer Time)

Displaying One Session

Channel 3 Proffered Paper session
Date
20.09.2020
Time
14:25 - 16:05
Room
Channel 3
Chairs
  • Eva Segelov (Clayton, NSW, Australia)
  • Jonathan Strosberg (Tampa, United States of America)
Proffered Paper session Proffered Paper session

1156O - Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)

Presentation Number
1156O
Lecture Time
14:25 - 14:37
Speakers
  • Jianming Xu (Beijing, China)
Room
Channel 3
Date
20.09.2020
Time
14:25 - 16:05

Abstract

Background

Surufatinib, a kinase inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptor 1 and colony stimulating factor-1 receptor, has demonstrated superior efficacy in extra-pancreatic neuroendocrine tumors (NETs) in a prior phase III study (ESMO 2019 Abs. LBA76). Here we report results from a parallel study of surufatinib in pancreatic NETs (pNETs).

Methods

The study evaluated the efficacy and safety of S in Pts with well-differentiated (pathological grade 1 or 2), progressive, unresectable or metastatic pNETs. Pts were randomized in a 2:1 ratio to receive S or P, 300 mg, orally, once daily, until disease progression or intolerable adverse events. Crossover at disease progression was allowed. The primary endpoint was investigator-assessed progression-free survival (PFS).

Results

By the cutoff date on 11 November 2019 for the pre-planned interim analysis, 172 Pts were randomized, 113 pts to S and 59 to P. Baseline characteristics were well balanced. The study met the primary endpoint; investigator-assessed median PFS was 10.9 vs. 3.7 months in S and P arms, respectively, with hazard ratio (HR)=0.491; 95% confidence interval [CI]: 0.319–0.755; p=0.0011. Analysis by a blinded independent radiology committee confirmed PFS improvement (13.9 vs. 4.6 months; HR=0.339; 95% CI: 0.209–0.549; p<0.0001). The investigator-assessed objective response rate was 19.2% with S and 1.9% with P (p=0.0021). Most common (≥5% in either arm) grade ≥3 treatment-emergent adverse events (TEAEs) were hypertension (38.9% in S arm vs. 8.5% in P arm), proteinuria (9.7% vs. 1.7%), hypertriglyceridaemia (7.1% vs. 0), alanine aminotransferase increased and gamma-glutamyltransferase increased (both 2.7% vs. 5.1%). TEAEs leading to drug discontinuation occurred in 10.6% pts vs. 6.8% pts in S and P arm respectively.

Conclusions

Surufatinib significantly improved the PFS in Pts with progressive, well-differentiated advanced pNETs. The safety profile was manageable and consistent with observations in prior studies. Surufatinib represents a promising treatment option in the armamentarium against pNETs.

Clinical trial identification

NCT02589821.

Legal entity responsible for the study

Hutchison MediPharma Limited.

Funding

Hutchison MediPharma Limited.

Disclosure

J. Li, S. Fan: Full/Part-time employment: Hutchison MediPharma Limited. W. Su: Shareholder/Stockholder/Stock options, Full/Part-time employment: Hutchison MediPharma Limited. All other authors have declared no conflicts of interest.

Collapse
Proffered Paper session Proffered Paper session

1160O - An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis

Presentation Number
1160O
Lecture Time
14:37 - 14:49
Speakers
  • Guillaume P. Nicolas (Basel, Switzerland)
Room
Channel 3
Date
20.09.2020
Time
14:25 - 16:05

Abstract

Background

177Lu-satoreotide tetraxetan (177Lu-IPN01072), a novel somatostatin receptor 2 (SSTR2) antagonist, showed promising efficacy in patients with progressive NETs associated with myelotoxicity at 7.4 GBq/cycle administered activity. This phase I/II study evaluates the safety and preliminary efficacy of this agent by adjusting treatment regimen to limit radiation dose to bone marrow and kidneys.

Methods

Eligibility included progressive grade 1/2 NETs. Phase I comprises parts A and B. Part A involved, subject to toxicity, planned administration of 3 cycles of 4.5 GBq of 177Lu-satoreotide tetraxetan with a peptide mass of 300 μg and enrolled 15 patients. After safety evaluation, part B proceeded with the radioactivity/peptide mass ratio per cycle being escalated up to 6.0 GBq/300 μg or 4.5 GBq/300-1300 μg; 20 patients were enrolled at the interim analysis (IA) cut-off date.

Results

Previous treatments of the 35 enrolled patients included surgery (69%), chemotherapy (20%), radiotherapy (14%), and prior or concomitant somatostatin analogues (77%). At the IA cut-off date, 28 had completed treatment, and 7 were still receiving planned cycles. Of these 28 patients, 22 (78.6%) had received 3 cycles with median cumulative radioactivity of ∼13 GBq, and 6 (21.4%) discontinued treatment. Overall, grade 3/4 related haematological adverse events (AEs) were reported in 12 patients (34.3%) with lymphopenia/decrease in lymphocyte counts in 6 (17.1%), thrombocytopenia/decrease in platelets count in 5 (14.3%), neutropenia in 2 (5.7%) and anemia in 1 (2.9%). No grade 3/4 renal toxicities were reported. For the 20 patients with adequate follow-up, disease control rate (DCR) at 12 months was 90% (95% CI: 68.3% - 98.8%).

Conclusions

This IA suggests that 177Lu-satoreotide tetraxetan has an acceptable safety profile in patients with NET using a lower administered activity per cycle than in earlier studies with this agent or current protocols using SSTR2 agonists. Promising efficacy results encourage the pursuit of its development in this indication.

Clinical trial identification

EudraCT: 2015-002867-41; NCT02592707.

Editorial acknowledgement

Partner 4 Health, France, provided medical writing support in accordance with Good Publication Practice (GPP3) guidelines.

Legal entity responsible for the study

Ipsen.

Funding

Ipsen.

Disclosure

C. Ansquer: Advisory/Consultancy: Advanced Accelerator Applications - France. N. Germann, S. McEwan: Full/Part-time employment: Ipsen. D. Wild: Advisory/Consultancy: Ipsen. R.J. Hicks: Advisory/Consultancy, Shareholder/Stockholder/Stock options, with proceeds donated to my institution: Telix Pharmaceuticals. All other authors have declared no conflicts of interest.

Collapse
Proffered Paper session Proffered Paper session

Invited Discussant 1156O and 1160O

Lecture Time
14:49 - 14:59
Speakers
  • Eva Segelov (Clayton, NSW, Australia)
Room
Channel 3
Date
20.09.2020
Time
14:25 - 16:05
Proffered Paper session Proffered Paper session

Q&A and live discussion

Lecture Time
14:59 - 15:09
Speakers
  • Eva Segelov (Clayton, NSW, Australia)
Room
Channel 3
Date
20.09.2020
Time
14:25 - 16:05
Proffered Paper session Proffered Paper session

1157O - A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)

Presentation Number
1157O
Lecture Time
15:09 - 15:21
Speakers
  • Jaume Capdevila (Barcelona, Spain)
Room
Channel 3
Date
20.09.2020
Time
14:25 - 16:05

Abstract

Background

Immune checkpoint blockade (ICB) has demonstrated limited activity in advanced NENs mainly due to the background biology of these “cold” neoplasms, with low tumor mutational burden, expression of PD-L1 and lymphocyte infiltration. Targeting both PD-L1 and CTLA-4 may increase the efficacy of ICB in NENs and revert the intrinsic resistance to this therapeutic approach.

Methods

Pts were recruited in four cohorts (C1-4): typical/atypical lung carcinoids (C1), G1/2 gastrointestinal (C2), G1/2 pancreatic (C3) and G3 NENs of gastroenteropancreatic origin (C4). All pts were included after progression to standard therapies for each C. Pts received durvalumab (D) 1500 mg up to 13 cycles and tremelimumab (T) 75 mg up to 4 cycles, every 4 weeks. Primary objective was 9-month (m) clinical benefit rate (CBR) for C1-3 and 9-m overall survival rate (OS) for C4. Assuming a 9mCBR P0/1 of 30%/50% for C1-3, and 9mOS P0/1 of 13%/23% for C4, (α=0,05 and 80% power) 28 pts in C1-3 and 30 pts in C4 were needed.

Results

123 pts were included. Median age 62-y, 59% male, 43% ECOG 0. With a median follow-up of 10.8 m, CBR at 9-m was 7.4%/32.3%/25% for C1/2/3 respectively. OS rate at 9-m for C4 was 36.1%. The irRECIST overall response rates (irORR) for C1-4 were 7.4%/0%/6.3%/9.1%, respectively. PD-L1 expression did not enrich for efficacy in either primary or secondary endpoints except for C1 group, where irORR was 16% in pts with PD-L1-positive tumors vs. 0% in pts with PD-L1 negative (p=0.033). Most common treatment-related AEs were fatigue (43%), diarrhea (31.7%), pruritus (23.6%), nausea (13.8%), and hypothyroidism (9.8%). Most frequent grade ≥3 treatment-related AEs were liver toxicity (9.7%), diarrhea (6.5%), fatigue and vomiting (2.4% each).

Conclusions

D+T combination showed modest activity in this heavily pretreated population. In high grade NENs, D+T reached the primary endpoint of increasing OS rate and deserves further evaluation. Objective radiological responses were infrequent. No new safety concerns have been observed in this large population of advanced NENs.

Clinical trial identification

EudraCT: 2016-002858-20; NCT03095274.

Legal entity responsible for the study

Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE).

Funding

AstraZeneca.

Disclosure

J. Capdevila: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): Ipsen; Advisory/Consultancy, Speaker Bureau/Expert testimony: Bayer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Research grant/Funding (institution), Research grant/Funding (institution): Principal investigator: Investigator initiated studies: Eisai; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Research grant/Funding (institution), Research grant/Funding (institution): Principal investigator: Investigator initiated studies: Advanced Accelerator Applications; Advisory/Consultancy, Speaker Bureau/Expert testimony: Amgen; Advisory/Consultancy, Speaker Bureau/Expert testimony: Sanofi; Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck Serono; Research grant/Funding (self), Research grant/Funding (institution), Research grant/Funding (institution): Principal investigator: Investigator initiated studies: AstraZeneca. A. Teule: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Ipsen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AAA; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AstraZeneca. C. López: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses, Research grant/funding (self): PI in clinical trials: Ipsen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): AAA; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses, Research grant/funding (self): PI in clinical trials: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses, Research grant/funding (self): PI in clinical trials: AstraZeneca. R. García-Carbonero: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: AAA; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Advanz Pharma; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Bayer; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: HMP; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Ipsen; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Merck; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Midatech Pharma; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): MSD; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): PharmaMar; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Pierre Fabre; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Roche; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Sanofi; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Servier; Research grant/Funding (institution): ARMO Sciences; Research grant/Funding (institution): Pharmacyclics; Research grant/Funding (institution): Boston Biomedicals; Research grant/Funding (institution): Amgen; Research grant/Funding (institution): Boehringer; Research grant/Funding (institution): Sysmex; Research grant/Funding (institution): Gilead Sciences; Research grant/Funding (institution): Adacap; Research grant/Funding (institution): VCN; Research grant/Funding (institution): Lilly; Non-remunerated activity/ies: Spanish Neuroendocrine Tumour Cooperative Group (GETNE); Non-remunerated activity/ies, Member of the Executive Committee: European Society of Neuroendocrine Tumours (ENETS); Non-remunerated activity/ies, Member of the Executive Committee: European Medicines Agency (EMA); Research grant/Funding (institution), Member of the Scientific Advisory Group for Oncology (2008-2017): AstraZeneca. M. Benavent: Speaker Bureau/Expert testimony: Pfizer; Speaker Bureau/Expert testimony: Ipsen; Speaker Bureau/Expert testimony: Novartis. A. Custodio: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Ipsen; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: AAA; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Bristol-Myers Squibb; Non-remunerated activity/ies, Senior leadership role: Grupo Español de Tumores Neuroendocrinos (GETNE); Non-remunerated activity/ies, Senior leadership role: European Society of Neuroendocrine Tumours (ENETS). V. Alonso: Advisory/Consultancy: Amgen; Speaker Bureau/Expert testimony: Merck Serono; Advisory/Consultancy: Roche; Speaker Bureau/Expert testimony: Sanofi Genzyme; Advisory/Consultancy: Servier; Advisory/Consultancy: Bayer; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Novartis. T. Alonso Gordoa: Advisory/Consultancy, Speaker Bureau/Expert testimony, Leadership role, Research grant/Funding (institution), Project lead in neuroendocrine tumours: Ipsen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Leadership role, Research grant/Funding (institution), Project lead in kidney cancer: Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy: Sanofi; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy, Research grant/Funding (institution): Astellas; Advisory/Consultancy, Research grant/Funding (institution): Janssen-Cilag; Advisory/Consultancy, Research grant/Funding (institution): MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Eisai; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): GSK-Novartis; Research grant/Funding (institution): Clovis; Research grant/Funding (institution): Nektar Therapeutics; Non-remunerated activity/ies, Member of the Spanish Germ Cell Tumors Board: Spanish Germ Cell Tumors; Non-remunerated activity/ies, Scientific advisor: Spanish Society of Medical Oncology (SEOM). G. Crespo: Advisory/Consultancy, Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony: Ipsen; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eisai; Advisory/Consultancy, Speaker Bureau/Expert testimony: Sanofi; Speaker Bureau/Expert testimony: Janssen; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eusa Pharma. M. Blanco-Codesido: Speaker Bureau/Expert testimony: Lilly; Speaker Bureau/Expert testimony: Ipsen; Speaker Bureau/Expert testimony: Roche; Research grant/Funding (self), Clinical Trial, PI: Beigene; Research grant/Funding (self), Clinical Trial, PI: Bristol-Myers Squibb; Research grant/Funding (self), Clinical Trial, PI: AAA; Research grant/Funding (self), Clinical Trial, PI: Five Prime Therapeutics. P. Jimenez-Fonseca: Travel/Accommodation/Expenses: Ipsen; Advisory/Consultancy: AAA; Speaker Bureau/Expert testimony: Sanofi; Speaker Bureau/Expert testimony: Leo Pharma; Speaker Bureau/Expert testimony: HR Pharmaceuticals; Non-remunerated activity/ies: Sociedad Española de Oncología Médica (SEOM); Non-remunerated activity/ies: Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE); Non-remunerated activity/ies: TTD; Non-remunerated activity/ies: European Neuroendocrine Tumor Society (ENETS). I. Sevilla: Advisory/Consultancy: Ipsen; Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy: PharmaMar; Speaker Bureau/Expert testimony: Amgen; Advisory/Consultancy: Bayer; Speaker Bureau/Expert testimony: AAA. M. Llanos: Advisory/Consultancy: Amgen; Speaker Bureau/Expert testimony: Merck; Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: Eisai; Speaker Bureau/Expert testimony: Servier; Speaker Bureau/Expert testimony: Ipsen; Speaker Bureau/Expert testimony: Lilly; Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Speaker Bureau/Expert testimony: Sanofi; Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Writing: Shire. J. Hernando-Cubero: Speaker Bureau/Expert testimony: Eisai; Speaker Bureau/Expert testimony: Ipsen; Speaker Bureau/Expert testimony: Novartis; Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: AAA; Speaker Bureau/Expert testimony: Angelini; Speaker Bureau/Expert testimony: Sanofi. J.L. Manzano: Advisory/Consultancy, Melanoma and Colo-Rectal Cancer (Advisory Role): Bristol-Myers Squibb; Advisory/Consultancy, Melanoma: Novartis; Advisory/Consultancy, Melanoma (Advisory Role): Pierre Fabre; Advisory/Consultancy, Melanoma: Roche; Advisory/Consultancy, Melanoma (Consultancy): MSD; Advisory/Consultancy, Colo-Rectal Cancer (Advisory Role): Amgen; Advisory/Consultancy, Colo-Rectal Cancer (Advisory Role): Merck. All other authors have declared no conflicts of interest.

Collapse
Proffered Paper session Proffered Paper session

1913O - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

Presentation Number
1913O
Lecture Time
15:21 - 15:33
Speakers
  • Mimi Hu (Houston, United States of America)
Room
Channel 3
Date
20.09.2020
Time
14:25 - 16:05

Abstract

Background

Pralsetinib is a highly potent, selective RET inhibitor targeting oncogenic RET alterations. We provide the registrational data for pts with RET+ MTC from the ARROW study.

Methods

ARROW (75 sites in 11 countries; NCT03037385) consists of a phase I dose escalation to establish the recommended phase II dose (400 mg once daily [QD] orally), and phase II expansion cohorts defined by tumour type and/or RET alteration. Primary phase II objectives are overall response rate (ORR; blinded independent central review per RECIST v1.1) and safety. We report efficacy for response-evaluable pts (REP) with RET+ MTC and safety for all pts who initiated pralsetinib 400 mg QD, both as of data cut-off date 13 Feb 2020.

Results

In 79 REP with RET+ MTC (mutation: 61% M918T, 28% C634X, 4% V804X, 8% other), ORR was 65% (95% CI, 53–75; n=51/79, 5% complete response [CR]; 59% partial response [PR; 1 pending confirmation]). ORR for pts with prior cabozantinib and/or vandetanib (C/V) was 60% (95% CI, 46–74; n=32/53; 2% CR; 58% PR [1 pending]) and in treatment-naïve pts ORR was 74% (95% CI, 49–91; n=14/19; 5% CR; 68% PR; all confirmed). Disease control rate was 97% (95% CI, 91–100); 99% (78/79) of pts experienced tumour shrinkage. Median progression-free survival (PFS) and duration of response (DOR) were not reached. In pts previously treated with C/V 18-mo PFS was 71% (95% CI, 58–85), and 18-mo DOR was 90% (95% CI, 77–100). In treatment-naïve pts, 18-mo PFS was 85% (95% CI, 65–100) and 86% (12/14) of responses were ongoing at data cut-off (up to 15 mo). Responses occurred regardless of RET genotypes (somatic or germline), including 5 of 6 pts with V804X gatekeeper mutation. In the safety population (n=438), treatment-related adverse events (TRAEs) were primarily grade 1–2; most common any-grade TRAEs were increased aspartate aminotransferase (34%), anaemia (24%), increased alanine aminotransferase (23%), constipation (23%) and hypertension (22%). 4% of pts discontinued due to TRAEs.

Conclusions

Pralsetinib demonstrated potent and durable clinical activity in RET+ MTC regardless of prior treatment with approved multikinase inhibitors or RET-mutation and was well tolerated.

Clinical trial identification

NCT03037385.

Editorial acknowledgement

Medical writing support was provided by Miriam Cohen, PhD, and editorial support was provided by Sinead Stewart, all of Paragon, Knutsford, UK, supported by Blueprint Medicines Corporation, Cambridge, MA according to Good Publication Practice guidelines.

Legal entity responsible for the study

Blueprint Medicines Corporation.

Funding

Blueprint Medicines Corporation.

Disclosure

M. Hu: Advisory/Consultancy: Blueprint Medicines Corporation; Advisory/Consultancy: Eli Lilly & Co; Advisory/Consultancy: Loxo Oncology; Advisory/Consultancy: Veracyte. V. Subbiah: Research grant/Funding (self): Roche/Genentech; Research grant/Funding (self): Novartis; Research grant/Funding (self): Bayer; Research grant/Funding (self): GSK; Research grant/Funding (self): Nanocarrier; Research grant/Funding (self): Vegenics; Research grant/Funding (self): Celgene; Research grant/Funding (self): Northwest Biotherapeutics; Research grant/Funding (self): Berghealth; Research grant/Funding (self): Incyte; Research grant/Funding (self): Fujifilm; Research grant/Funding (self): PharmaMar; Research grant/Funding (self): D3; Research grant/Funding (self): Pfizer; Research grant/Funding (self): Multivir; Research grant/Funding (self): Amgen; Research grant/Funding (self): AbbVie; Research grant/Funding (self): Alfa-sigma; Research grant/Funding (self): Agensys; Research grant/Funding (self): Boston Biomedical; Research grant/Funding (self): Idera Pharma; Research grant/Funding (self): Inhibrx; Research grant/Funding (self): Exelixis; Research grant/Funding (self): Blueprint Medicines Corporation; Research grant/Funding (self): Loxo Oncology; Research grant/Funding (self): MedImmune; Research grant/Funding (self): Altum; Research grant/Funding (self): Dragonfly Therapeutics; Research grant/Funding (self): Takeda; Research grant/Funding (self): National Comprehensive Cancer Network. L.J. Wirth: Advisory/Consultancy: Bayer; Advisory/Consultancy: Blueprint Medicines Corporation; Advisory/Consultancy: Cue Biopharma; Advisory/Consultancy: Eisai; Advisory/Consultancy: Exelixis; Advisory/Consultancy: Genentech; Advisory/Consultancy: Lilly; Advisory/Consultancy: Loxo Oncology; Advisory/Consultancy: Merck; Advisory/Consultancy: Rakuten Medical. M. Schuler: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: Novartis; Advisory/Consultancy: Roche; Advisory/Consultancy: Takeda; Advisory/Consultancy: MorphoSys. A.S. Mansfield: Honoraria (institution): AbbVie; Honoraria (institution): AstraZeneca; Honoraria (institution): BMS; Honoraria (institution): Roche/Genentech; Travel/Accommodation/Expenses: Novartis; Research grant/Funding (institution): Verily Research; Non-remunerated activity/ies: Mesothelioma Applied Research Foundation. M.S. Brose: Honoraria (self), Research grant/Funding (institution): Exelixis; Advisory/Consultancy, Research grant/Funding (institution): Blueprint Medicines Corporation; Advisory/Consultancy, Research grant/Funding (institution): Lilly; Honoraria (self), Advisory/Consultancy: Bayer; Honoraria (self), Advisory/Consultancy: Eisai; Honoraria (self): Raffo; Advisory/Consultancy: Loxo. G. Curigliano: Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Seattle Genetics; Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Foundation Medicine; Advisory/Consultancy, Speaker Bureau/Expert testimony: NanoString; Advisory/Consultancy, Speaker Bureau/Expert testimony: Samsung; Advisory/Consultancy, Speaker Bureau/Expert testimony: Celltrion; Non-remunerated activity/ies: Ellipsis; Speaker Bureau/Expert testimony: BMS; Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy: Mylan. S. Leboulleux: Advisory/Consultancy: Lilly; Advisory/Consultancy: Bayer; Speaker Bureau/Expert testimony: Eisai. V.W. Zhu: Honoraria (self): AstraZeneca; Honoraria (self): Roche/Foundation Medicine; Honoraria (self): Roche/Genentech; Honoraria (self): Takeda; Shareholder/Stockholder/Stock options: TP Therapeutics. B. Keam: Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): MSD Oncology; Advisory/Consultancy: ABL Bio; Advisory/Consultancy: Genexine; Advisory/Consultancy: Cellid; Advisory/Consultancy: Ono Pharmaceutical. I. Matos: Research grant/Funding (self): Roche. C-C. Lin: Advisory/Consultancy: Blueprint Medicines Corporation; Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Daiichi Sankyo; Honoraria (self), Advisory/Consultancy: Novartis; Advisory/Consultancy: Takeda; Honoraria (self): BMS; Honoraria (self): Roche; Travel/Accommodation/Expenses: BeiGene; Travel/Accommodation/Expenses: Eli Lilly. D. Adkins: Advisory/Consultancy: Lilly; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Celgene; Advisory/Consultancy: Merck; Advisory/Consultancy: CUE; Advisory/Consultancy: Aduro; Advisory/Consultancy: KURA; Advisory/Consultancy: Oncolys; Advisory/Consultancy: Enzychyme; Advisory/Consultancy: Matrix; Advisory/Consultancy: Celldex. C.S. Baik: Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Research grant/Funding (self): Celgene; Research grant/Funding (self): Novartis; Research grant/Funding (self): MedImmune; Research grant/Funding (self): SWOG; Research grant/Funding (self): Genentech; Research grant/Funding (self): Loxo Oncology; Research grant/Funding (self): Pfizer; Research grant/Funding (self): Spectrum Pharmaceuticals; Research grant/Funding (self): Blueprint Medicines Corporation; Research grant/Funding (self): Daiichi Sankyo; Research grant/Funding (self): Rain Therapeutics; Research grant/Funding (self): AbbVie; Research grant/Funding (self): TP Therapeutics; Research grant/Funding (self): Lilly Oncology. G. Lopes: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Honoraria (self), Travel/Accommodation/Expenses: Boehringer Ingelheim; Travel/Accommodation/Expenses: E R Squibb Sons; Research grant/Funding (institution), Travel/Accommodation/Expenses: Janssen; Research grant/Funding (institution): MSD; Research grant/Funding (institution): EMD Serono; Research grant/Funding (institution): Blueprint Medicines Corporation; Research grant/Funding (institution): Tesaro; Research grant/Funding (institution): Bavarian Nordic; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): G1 Therapeutics; Research grant/Funding (institution): Adaptimmune; Research grant/Funding (institution): BMS; Research grant/Funding (institution): GSK; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Rgenix; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Lilly. D. Sarker: Honoraria (self): Pfizer; Honoraria (self): Bayer; Advisory/Consultancy: Ipsen; Honoraria (self): Novartis; Advisory/Consultancy: Eisai; Advisory/Consultancy: Surface Oncology; Advisory/Consultancy: MSD Oncology. H. Zhang, C. Turner: Shareholder/Stockholder/Stock options, Full/Part-time employment: Blueprint Medicines Corporation. M. Taylor: Advisory/Consultancy, Speaker Bureau/Expert testimony: BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eisai; Advisory/Consultancy: Array BioPharma; Advisory/Consultancy: Loxo Oncology; Advisory/Consultancy: Bayer; Advisory/Consultancy: ArQule; Advisory/Consultancy: Blueprint Medicines Corporation; Advisory/Consultancy: Novartis; Advisory/Consultancy: Sanofi/Genzyme; Speaker Bureau/Expert testimony: Merck. All other authors have declared no conflicts of interest.

Collapse
Proffered Paper session Proffered Paper session

Invited Discussant 1157O and 1913O

Lecture Time
15:33 - 15:43
Speakers
  • Nicola Fazio (Milan, Italy)
Room
Channel 3
Date
20.09.2020
Time
14:25 - 16:05
Proffered Paper session Proffered Paper session

Q&A and live discussion

Lecture Time
15:43 - 15:53
Speakers
  • Eva Segelov (Clayton, NSW, Australia)
Room
Channel 3
Date
20.09.2020
Time
14:25 - 16:05